Checkpoint inhibitors in the first-line treatment of non-small cell lung cancer
|
|
- Francis Copeland
- 5 years ago
- Views:
Transcription
1 380 Checkpoint inhibitors in the first-line treatment of non-small cell lung cancer L. Decoster, MD 1, K. Vekens, MD 2, S. Mignon, MD 1, D. Schallier, MD, PhD 1, J. De Grève, MD, PhD 1 SUMMARY Antibodies against programmed cell death-1 (PD-1) and its ligand (PD-L1) have become standard-of-care in the second-line treatment for advanced non-small cell lung cancer after failure of first-line chemotherapy. The observed durable responses as well as the favourable toxicity profile have moved these agents to firstline studies for advanced non-small cell lung cancer. In tumours with high PD-L1 expression, pembrolizumab is registered as the preferred first-line treatment. Further studies are currently focusing on combination strategies. The major future challenge will be selecting the optimal treatment strategy for the patient. (BELG J MED ONCOL 2017;11(8): ) INTRODUCTION In locally advanced or metastatic non-small-cell lung cancer (NSCLC) without targetable driver mutations, platinum-doublet chemotherapy has been the standard-of-care for the past three decades. The proportion of patients who achieve response to first-line chemotherapy is 25-35%, but these responses are rarely durable with a median progression free survival (PFS) of four to six months and a median overall survival (OS) of eight to ten months. 1 In addition, chemotherapy is associated with moderate to severe toxicities. Immune checkpoints inhibitors, such as antibodies targeting the cytotoxic T-lymphocyte associated protein 4 (ctla4) and the programmed cell death-1 (PD-1) protein or the PD ligand 1 (PD-L1), are rapidly reshaping the therapeutic landscape of different tumour types, including NSCLC. Four randomised phase III studies in NSCLC have demonstrated superior activity of the PD-1 inhibitors nivolumab (CheckMate 017 and 057) and pembrolizumab (Keynote 010) and the PD-L1 inhibitor atezolizumab (OAK) over docetaxel chemotherapy in second-line and beyond, with response rates of approximately 20% and significant improvements in OS. 2-5 In addition, treatment with an anti- PD-(L)1 inhibitor resulted in durable responses, decreased toxicity and improved quality-of-life when compared to docetaxel. As a result, PD-1 blockade has become a new standard-of-care for patients with advanced NSCLC who experience progression on or after a platinum-based chemotherapy. The observed activity and improved tolerability of PD-1/ PD-L1 inhibitors in second-line setting for NSCLC have increased the interest in moving these agents to the front-line setting. This review summarises the current knowledge on first-line immunotherapy treatment for advanced NSCLC (Table 1). 1 Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Brussel, Belgium, 2 Department of Pulmonology, UZ Brussel, Vrije Universiteit Brussel, Brussel, Belgium. Please send all correspondence to: L. Decoster, MD, Oncologisch Centrum, Department of Medical Oncology, Laarbeeklaan 101, 1090 Brussel, Belgium, tel: , lore.decoster@uzbrussel.be. Conflict of interest: The authors have nothing to disclose and indicate no potential conflict of interest. Keywords: checkpoint inhibitors, first-line, non-small cell lung cancer. VOLUME11DECEMBER2017
2 PHARMACOTHERAPY 381 TABLE 1. Overview of the reported first -line studies in non-small cell lung cancer with immunotherapy. Study drug(s) Study Name (reference) Phase Compared with Patient selection Patient number Response (%) PFS OS AE Anti-PD-(L)1 monotherapy Pembrolizumab Keynote 024 (7) 3 CT Yes, PD- L1 50% vs 27.8 mpfs 10.3 m vs 6 m; 6mOS 80% vs 72% Any grade: 73 vs 90% Grade 3/4: 27 vs 53% Nivolumab Checkmate 012 (8) 1 No mpfs 3.6m PFS24w 41% mos 19.4m 1y0S 73% Any grade: 71% Grade 3/4: 19% Nivolumab Checkmate 026 (9) 3 CT Yes PD- L1 1% 541 mpfs 4.2 vs 5.9m Durvalumab 1108 study (10) 1/2 NA No NR NR Any grade: 56% Grade 3/4 : 10% Avelumab Javelin solid tumour (11) 1 NA No mpfs 4m PFS 24w 37% NR Any grade: 66% Grade 3/4: 11% Anti-cTLA4/anti PD-(L)1 combination Ipilimumab/ Nivolumab CheckMate 012 (15) 1 NA No mpfs m PFS 24w 47-68% 1yOS 69% Any grade: 72-82% Grade 3/4: 33-37% Anti-cTLA4/chemotherapy combination Ipilimumab/ carboplatinum/paclitaxel (18) 2 Concurrent vs Phased vs CT No vs 32 vs 14 mpfs 4.1 vs 5.1 vs 4.2m mos 9.7 vs 12.2 vs 8.3m 1yOS 42 vs 50 vs 39% Any grade: 76% vs 82 % vs 80% Grade 3/4: 41% vs 39% vs 37% Anti-PD-(L)1/chemotherapy combination Nivolumab/ platinum- doublet CheckMate 012 (19) 1 NA No mpfs m PFS24w 38-71% mos m 1y0S 5à-87% Any grade: 95% Grade 3/4: 45% Pembrolizumab/ carboplatinum/ pemetrexed Keynote-021 (20) Atezolizumab/ platinum doublet GP28328 (21) 2 CT No vs 29 mpfs 13 vs 8.9m NR Any grade: 94% vs 90% Grade 3/4: 40% vs 25% 1b NA No NR NR Any grade: 98% Grade 3/4 : 78% Abbreviations: PFS: Progression Free Survival; OS: Overall Survival; AE: Adverse Events; NA: Not applicable; NR: Not Reported; m: months; y: year; vs: versus; CT: chemotherapy. MECHANISM OF ACTION OF CHECKPOINT INHIBITORS To mediate anti-tumour responses, T cells must be specific for cancer cells and activated into an effector state. The process of T cell activation involves an antigen presentation to the corresponding T cell receptor on naïve T cells. In addition, a second co-stimulatory signal by interaction of B7 on an antigen-presenting cell with CD28 on the T cell is required for full activation of the T cells. This is regulated by inhibitory checkpoints to avoid collateral damage and autoimmunity. In the lymph nodes, the ctla4 receptor on activated T cells competes with CD28 for B7 ligands and subsequently down- VOLUME11DECEMBER20178
3 382 FIGURE 1. Overall survival for pembrolizumab versus platinum-doubled in the first line treatment of non-small cell lung cancer. regulates the T cell function. The anti-ctla4 antibodies reactivate T cells by facilitating the CD28-B7 binding. In the tumour microenvironment, the PD1 checkpoint receptor, expressed by activated T cells, will bind with the PD-L1 receptor expressed by the tumour cells in order to suppress T cell activation. In NSCLC, approximately 60% of patients present with a PD-L1 expressing tumour. 6 Antibodies blocking either PD-1 or PD-L1 can unleash the activated tumour-reactive T cells. IMMUNE CHECKPOINTS AS MONOTHERAPY IN FIRST-LINE FOR NSCLC Two first-line phase III studies have compared an anti-pd1 antibody to platinum-based chemotherapy with variable success. In the randomised, open-label phase III Keynote-024 trial, pembrolizumab was compared to first-line platinum-doublet chemotherapy for patients with advanced NSCLC and a PD-L1 tumour proportion score of 50% or greater. 7 In this trial, there was an increase of the objective RR (45% versus 28%) and a prolongation of the median PFS (10.3 months versus 6.0 months; HR 0.50; p<0.001). In addition, although median OS was not reached in either group there was a significant prolongation of the OS at six months in the pembrolizumab group (80.2% versus 72.4%, HR 0.60; p=0.005) (Figure 1). As in the second-line studies, all grades adverse events were less frequent for pembrolizumab (73% versus 90%) and grade 3-4 treatment-related adverse events occurred in twice as many patients in the chemotherapy group (53% versus 27%). This also means that more than a quarter of patients on immunotherapy have no toxicity at all. Immune related adverse events were more frequent with pembrolizumab (29% with 10% grade 3-4) and cytopaenias (anaemia 44%, neutropenia VOLUME11DECEMBER2017
4 PHARMACOTHERAPY % with 13% grade 3-4 and thrombocytopenia 11%) were more frequent with chemotherapy, consistent with the mechanism of action of each treatment. Since pembrolizumab was associated with longer PFS and OS and fewer treatment-related adverse events than platinum-based chemotherapy, this treatment received FDA and EMA registration as first-line treatment for NSCLC with high PD-L1 expression of 50% and is currently reimbursed in Belgium for this indication. Interestingly, the same success was not observed in the CheckMate 026 trial. In this randomised phase III trial nivolumab was compared to first-line platinum-doublet chemotherapy for patients with advanced NSCLC and a PD-L1 expression of 1%. In addition PD-L1 expression of <5% versus 5% was a stratification factor at randomisation. A prior phase I study (CheckMate 012) demonstrated clinical activity with nivolumab in the first line treatment for NSCLC regardless of PD-L1 expression but with higher RR in patients whose tumours expressed PD-L1 and with a trend toward greater response as PD-L1 expression level increased. 8 In the phase III trial, CheckMate 026, nivolumab did not improve PFS compared to platinum-based chemotherapy (4.2 versus 5.9 months; HR 1.15; p=0.25). 9 The anti-pdl-1 antibodies durvalumab and avelumab have also been studied in early phase first-line trials. In the 1108 study, durvalumab monotherapy led to an objective RR of 27% and a disease control rate at 24 weeks of 42%. 10 In this trial the RR was higher for tumours with high PD-L1 expression ( 25%) versus tumours with lower PD-L1 expression (RR 29% versus 11%). In the phase I Javelin solid tumour trial the objective RR for avelumab monotherapy in the NSCLC cohort was 22% with a PFS at 24 weeks of 37%. 11 Different trials investigating the efficacy of an anti-pd-(l)1 antibody in the first-line setting versus chemotherapy are still ongoing, including Keynote 042 of pembrolizumab in patients with advanced NSCLC with a PD-L1 expression 1% (NCT ), IMpower 110 and 111 with atezolizumab in respectively PD-L1 positive non-squamous NSCLC (NCT ) and squamous NSCLC (NCT ) and Javelin Lung 100 with avelumab (NCT ). 12 DUAL CHECKPOINT BLOCKADE ctla-4 and PD-1 inhibit anti-tumour immunity through complementary and non-redundant mechanisms. These non-overlapping mechanisms of action of anti-ctla4 and anti-pd-(l)1 antibodies make combination of these two classes of checkpoint inhibitors an interesting strategy. Preclinical models have shown that dual blockade, as compared with blockade of either pathway alone, synergistically improves anti-tumour responses. 13 In melanoma, the highest RR and PFS were observed with the combination of ipilimumab and nivolumab (RR 57.6% and PFS 11.5 months) in comparison with nivolumab monotherapy (RR 43.7% and PFS 6.9 months (HR 0.74)) and ipilimumab monotherapy (RR 19% and PFS 2.9 months (HR 0.42; p<0.001)). This improved PFS compared to nivolumab was mainly observed in the PD-L1 negative tumours (11.2 months versus 5.3 months). However, the observed increased activity was at the expense of a higher frequency of serious treatment-related adverse events (55% for the combination arm versus 16.3% for nivolumab monotherapy). 14 In the CheckMate 012 phase I trial, two cohorts combined nivolumab every two weeks with ipilimumab either every twelve weeks or every six weeks. 15 This combination resulted in a RR of 38-47%, a median PFS of four to eight months and a one-year survival of 69%. The RR of the nivolumab/ipilimumab combination was enhanced with increasing PD-L1 expression: 21% for a PD-L1 expression of <1%; 57% for a PD-L1 expression of 1% and 92% for a PD-L1 expression of 50%. In addition the one-year OS for this last group of patients was 100%. In this study grade 3-4 adverse events seemed more frequent than observed for anti-pd-1 monotherapy (33-37%). The first-line combination of nivolumab/ ipilimumab is currently under investigation in a phase III study, CheckMate 227 (NCT ). 12 Two other ongoing trials investigating the combination of durvalumab with tremelimumab are ongoing (MYSTIC: NCT and NEPTUNE: NCT ). 12 COMBINATION OF CHECKPOINT INHIBITOR WITH CHEMOTHERAPY IN FIRST-LINE Although conventional chemotherapy may be immunosuppressive because of the myelodepression, it may also stimulate anti-cancer immunity through various mechanisms: 1) induction of immunogenic cell death with tumour antigen release which can activate dendritic cells and consequently specific T cell response, 2) elimination of immunosuppressive cells and 3) sensibilisation of tumour cells to immune effector cells. 16,17 For this reason, there is a strong rationale to combine chemotherapy with checkpoint inhibitors. Early phase studies have combined chemotherapy with either anti-ctla4 or anti-pd-(l)1 antibodies. In a randomised phase II trial in NSCLC carboplatinum/paclitaxel chemotherapy was combined with ipilimumab in two different regimens: either concurrent ipilimumab (four doses of ipilimumab plus chemotherapy followed by two doses of placebo plus chemotherapy) or phased ipilimumab (two doses of placebo plus chemotherapy followed by four doses of ipilimumab plus chemotherapy). The study resulted in an improved PFS for the phased ipilimumab regimen (HR VOLUME11DECEMBER20178
5 384 KEY MESSAGES FOR CLINICAL PRACTICE 1. Pembrolizumab has become standard-of-care for the first-line treatment of advanced NSCLC with a PD- L1 expression of 50%. It is the only immunotherapy registered and reimbursed in the first line setting so far. 2. Phase III trials combining different types of immunotherapy or immunotherapy and chemotherapy are ongoing. 3. PD-L1 expression is an enrichment biomarker for response to immunotherapy in NSCLC, but other markers may be even more important for the immune response against the tumour. Predictive biomarkers are needed in order to select the optimal first-line treatment strategy for patients with advanced NSCLC. 0.69; p=0.02) but not for the concurrent regimen (HR 0.88; p=0.25). 18 In a phase I trial nivolumab was combined with four cycles of a platinum-doublet chemotherapy followed by nivolumab monotherapy. 19 In this trial, the RR varied from 33-47% and the median OS ranged from 11.1 to 19.2 months. In addition, no dose limiting toxicities were observed. In this small study no increased efficacy was observed with higher PD-L1 expression. The nivolumab/platinum-doublet chemotherapy combination is currently being investigated in the Check- Mate 227 trial (NCT ). 12 In the randomised phase II study Keynote-021, patients with advanced non-squamous NSCLC were treated with carboplatin-pemetrexed chemotherapy with or without pembrolizumab. 20 Both objective RR (55 versus 29%, p=0,0016) and median PFS (13,0 versus 8,9 months; HR 0.53; p=0,01) favoured the pembrolizumab-chemotherapy combination over chemotherapy alone but there was no difference in OS between the two groups (HR 0.90; p=0.39) possibly because of a cross over in the chemotherapy alone group. In this phase II study the incidence of both any grade and grade 3-4 adverse events was similar for both groups (93% versus 90% and 39% versus 26%, respectively). Based on these results the FDA granted accelerated approval to pembrolizumab for use in combination with carboplatin plus pemetrexed as front line treatment for patients with metastatic or advanced non-squamous NSCLC, regardless of PD-L1 expression in May A phase III trial (Keynote-189) combining platinum-pemetrexed chemotherapy with pembrolizumab in non-squamous NSCLC is ongoing (NCT ). The anti-pd-l1 antibody atezolizumab also demonstrated a promising RR (50-76%) in combination with chemotherapy. 21 Different phase III trials combining atezolizumab with chemotherapy are ongoing (IMpower 130 in non-squamous NSCLC (NCT ), IMpower 131 in squamous NS- CLC (NCT )). 12 CONCLUSION The emergence of immunotherapy in NSCLC has drastically changed the landscape of the management of this deadly disease, offering the potential for a durable response and a prolonged survival. Based on the results of the Keynote-024 trial, pembrolizumab has become the new standard-of-care for the firstline treatment of NSCLC with a high PD-L1 expression of 50%. 7 Pembrolizumab is currently the only immunotherapy approved and reimbursed in the first-line setting. Other immunotherapy drugs have so far not demonstrated any benefit over chemotherapy in the first-line setting. Combination strategies are under investigation in an attempt to further increase the number of patients potentially benefiting from immunotherapy. 12 In May 2017, the combination of pembrolizumab with chemotherapy carboplatin and pemetrexed received accelerated approval based on phase II results. However, this combination also seems to increase the toxicity and is further being explored in a phase III trial For this reason, the challenge in advanced NSCLC in the coming years will be the identification of an individualised optimal treatment strategy in the first-line setting. Patient selection will be crucial. So far PD-L1 expression seems to be an enrichment biomarker for the response to immunotherapy in NSCLC. However other factors beyond PD-L1 expression such as tumour mutational load or patient s immune profile may be important for the immune response against the tumour and research should therefore continue to focus on the identification of potential biomarkers. 22,23 REFERENCES 1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Eng J Med. 2002;346: Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Eng J Med. 2015;373: Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Eng J Med. 2015;373: VOLUME11DECEMBER2017
6 PHARMACOTHERAPY Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1 positive, advanced non-small-cell lung cancer (KEY- NOTE-010): a randomised controlled trial. Lancet. 2016;387: Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicenter randomised controlled trial. Lancet. 2017;389: Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Eng J Med. 2015;372: Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Eng J Med. 2016;375: Gettinger S, Rizvi NA, Chow LQ, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34: Sonciski M, Creelan B, Horn L, et al. CheckMate 026: A Phase 3 trial of nivolumab vs Investigator s choice (IC) of platinum-doublet chemotherapy (PT- DC) as first line therapy for stage IV/recurrent programmed death ligand 1 (PD- L1) positive NSCLC. Ann of Oncol. 2016;27, suppl 6: abstract LBA7_PR (ESMO 2016). 10. Antonia SJ, Brahmer JR, Khleif S, et al. Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer. Ann of Oncol. 2016;27, suppl 6: Jerusalem G, Chen F, Spigel D, et al. Javelin solid tumour: safety and clinical activity of avelumab (anti-pd-l1) as first line treatment in patients with advanced NSCLC. J Thorac Oncol. 2017; 12 (suppl):s Selby MJ, Engelhardt JJ, Johnston RJ, et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumour models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS One. 2016;11(11):e Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Eng J Med. 2015;373: Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18: Apetoh L, Ladoire S, Coukos G, et al. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol. 2015;26: Galluzzi L, Buque A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28: Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatinum as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomised, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17): Rizvi NA, Hellmann MD, Brahmer J, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-smallcell lung cancer. J Clin Oncol. 2016;34(25): Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatinum and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11): Liu S, Powderly JD, Camidge DR, et al. Safety and efficacy of MPDL3280A (anti-pdl1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2015:33 (abstract 8030). 22. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348: Tiseo M, Veneziani M, Gelsomino F, et al. Circulating immune-profile as predictor of outcome in NSCLC patients treated with nivolumab. Ann of Oncol. 2017;28 (suppl 2):ii9-ii13. Call for Oncothesis Share your thesis with your colleagues! At the Belgian Journal of Medical Oncology (BJMO) we are constantly looking for interesting doctoral theses in oncology. The BJMO is an ideal platform to share your research with your colleagues and peers. The BJMO is the official platform of the Belgian Society of Medical Oncology (BSMO) and the Belgian Association for Cancer Research (BACR) and as such offers optimal visibility in the Belgian oncology community. All article submissions or requests for additional information are most welcome at editor@bjmo.be VOLUME11DECEMBER20178
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer
Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationPD-(L)1 Inhibitors and CTLA-4 Inhibitors: Rationale for Combinations and Recent Data in Non-Small Cell Lung Cancer
PD-(L)1 Inhibitors and CTLA-4 Inhibitors: Rationale for Combinations and Recent Data in Non-Small Cell Lung Cancer Rebecca S. Heist, MD, MPH Abstract The recent success of PD-1 and PD-L1 inhibitors in
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationNon-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT
Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationAlessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona
GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationIMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER
IMMUNOTHERAPY FOR THE TREATMENT OF LUNG CANCER A guide for patients and caregivers TM Content is consistent with the Oncology Nursing Society Standards and Guidelines. The ONS Seal of Approval does not
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationLung cancer PD-L1 testing clinical impact
Lung cancer PD-L1 testing clinical impact Korinna Jöhrens Institute for pathology Carl Gustav Cars Universitätsklinikum Dresden, Germany Medical consultant QuIP Immune therapy with checkpoint-inhibitors
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationCurrent status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
REVIEW 2018 Sep 3. [Epub ahead of print] https://doi.org/10.3904/kjim.2018.179 Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer Sung Won Lim and Myung-Ju Ahn Division
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationNewest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management
Newest Oncology Agents: PD 1 Inhibitors Clinical Information and Patient Management Stacey Jassey Megan Brafford David Kwasny This CE activity was originally presented live at the 2015 NASP Annual Meeting
More informationUpdates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer
Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Benjamin Besse, MD, PhD Chair, EORTC Lung Group Chair, Gustave Roussy Thoracic Unit Villejuif, France What
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationLung cancer, elderly and immune checkpoint inhibitors
Review Article Lung cancer, elderly and immune checkpoint inhibitors Francesca Casaluce 1, Assunta Sgambato 1, Paolo Maione 1, Alessia Spagnuolo 1,2, Cesare Gridelli 1 1 Division of Medical Oncology, S.
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationImmunotherapy for non-small cell lung cancer: from clinical trials to real-world practice
Editorial Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice Sawsan Rashdan 1,2, David E. Gerber 1,2,3 1 Division of Hematology-Oncology, Department of Internal Medicine,
More informationImmunoterapia e farmaci innovativi
Immunoterapia e farmaci innovativi Emilio Bria Oncologia Medica, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Padova, 29 Ottobre 2015 Disclosures Advisory
More informationINMUNOTERAPIA II. Dra. Virginia Calvo
INMUNOTERAPIA II Dra. Virginia Calvo LBA53. IMpower130. Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with o without atezolizumab
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationSurvival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review
/, 2017, Vol. 8, (No. 31), pp: 51779-51785 Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review Bum Jun Kim 1, Jung Han
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationImmunotherapy in NSCLC
Immunotherapy in NSCLC Enriqueta Felip Hospital Vall d Hebron University, Barcelona SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, January 27 217 Immunotherapy in NSCLC: Outline 1 st line as
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationHistology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
More informationStato dell arte dell immunoterapia. Il Paziente con NSCLC Francesco Ferraù Oncologia Medica Ospedale S.Vincenzo, Taormina
I CONVEGNO REGIONALE SIFO MEETING DI PRIMAVERA IL FARMACISTA CLINICO E I NUOVI MODELLI DI CURA Taormina, 11/12/13 maggio 217 Stato dell arte dell immunoterapia. Il Paziente con NSCLC Francesco Ferraù Oncologia
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationA review of guidelines for lung cancer
Review Article A review of guidelines for lung cancer Paolo Bironzo 1, Massimo Di Maio 2 1 Division of Thoracic Oncology, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano,
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationEvaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a metaanalysis
Original Article Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a metaanalysis Yang-Bo Hu 1 *, Qun Zhang 2,3 *, Hui-Juan Li 4,
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationOverall survival in non-small cell lung cancer what is clinically meaningful?
Editorial Overall survival in non-small cell lung cancer what is clinically meaningful? Klaus Fenchel 1, Ludger Sellmann 2, Wolfram C. M. Dempke 3 1 Medical School Hamburg (MSH), Hamburg, Germany; 2 University
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationPersonalized Treatment Approaches for Lung Cancer
Personalized Treatment Approaches for Lung Cancer California Thoracic Society 2018 Annual Carmel Conference January 27, 2018 Matthew Gubens, MD, MS Associate Professor of Medicine Chair, Thoracic Oncology
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationVOLUME12M A R C H2018 SUMMARY INTRODUCTION
61 Second-line treatment of non-small cell lung cancer adenocarcinoma patients not harbouring an oncogene driver mutation anno 2017-2018: A consensus group meeting P-E. Baugnée, MD 1, L. Bosquée, MD 2,
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationSquamous Cell NSCLC: Differentiating Between Progression and Pseudoprogression
Squamous Cell NSCLC: Differentiating Between Progression and Pseudoprogression David R. Spigel, M.D. Program Director, Lung Cancer Research Sarah Cannon Research Institute Nashville, TN Case of NR: Initial
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationDebaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationYoung Kwang Chae 1,2,3*, Ayush Arya 1, Wade Iams 3, Marcelo R. Cruz 1, Sunandana Chandra 1,2,3, Jaehyuk Choi 2,3 and Francis Giles 1,2,3
Chae et al. Journal for ImmunoTherapy of Cancer (2018) 6:39 https://doi.org/10.1186/s40425-018-0349-3 REVIEW Current landscape and future of dual anti- CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer;
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More information